On June 27, 2024 EditCo Bio, Inc., a leader in genome engineering innovation, reported the expansion of its T-cell editing portfolio with the launch of Knockout CD8+ T-cell Pools (Press release, EditCo Bio, JUN 27, 2024, View Source [SID1234644588]). This new addition builds upon the success of their Knockout CD4+ T-cell Pools, offering researchers an advanced tool for primary T-cell editing that brings unprecedented precision and scalability to cancer and immunotherapy research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Leveraging EditCo Bio’s cutting-edge automated platform, the new Knockout CD8+ T-cell Pools allow researchers to bypass challenging optimization steps and access highly functional edited T-cells ready for immediate use. This innovation accelerates the transition from research discovery to clinical application and delivers several key benefits:
Accelerated results: EditCo Bio’s unique 7-day protocol and proprietary guide RNA technology achieve knockout efficiencies approaching 100% in primary human CD8+ T-cells. Additionally, EditCo has several prescreened and optimized donor cells available to kick off projects immediately.
Dependable performance: Edited CD8+ T-cell pools demonstrate exceptional editing efficiency (~100%) and viability (>85%). with editing efficiency unchanged for at least 4 weeks in culture.
Enhanced functionality: Edited CD8+ T-cell pools showed antigen-specific CD107a mobilization, a hallmark of cytotoxic activity.
Customizable solutions: EditCo Bio can efficiently onboard customer-supplied donor cells, ensuring high knockout efficiencies, viability, and turn-around times tailored to specific project needs.
"For researchers working on the front lines of immunotherapy, having access to high-quality CD8+ T-cells can significantly accelerate the pace of discovery and therapeutic development," said Travis Maures, CSO of EditCo Bio. "Our new Knockout CD8+ T-cell Pools provide the precision, efficiency, and scalability needed to push the boundaries of what’s possible in cellular research."
The addition of Knockout CD8+ T-cell Pools further strengthens EditCo Bio’s comprehensive Engineered Cell portfolio, solidifying its position as a leader in cell engineering solutions. The company plans to continue to expand its range of edited primary cell products to include other primary cell subsets, which will be available later this year.
For more information regarding EditCo Bio’s Knockout T-cell Pools, visit www.EditCo.bio/contact.